Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel)

American Journal of Obstetrics and Gynecology

Volumn 177, Issue 6, 1997, Pages 1413-1418

  Adamson, G D ^a   Heinrichs, W L ^a   Henzl, M R ^a   Yuzpe, A A ^a   Bergquist, C ^a   Jacobson, J J ^a   Eriksson, S ^a   Kwei, L ^a   Gilbert, S M ^a  

^a Fertility Physicians of Northern California   (United States)

Author keywords

Bone mineral density; Endometriosis; Gonadotropin releasing hormone; Nafarelin

Indexed keywords

ESTRADIOL; GONADORELIN DERIVATIVE; NAFARELIN; NAFARELIN ACETATE;

ADULT; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOMETRIOSIS; FEMALE; HOT FLUSH; HUMAN; INTRANASAL DRUG ADMINISTRATION; MULTICENTER STUDY; PHOTON ABSORPTIOMETRY; PRIORITY JOURNAL;

EID: 0031446230     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(97)70084-X     Document Type: Article

References (16)

1. KG Waller RW. Shaw Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long term follow-up Fertil Steril 59 1993 511 515
2. L Speroff R Glass N. Kase Clinical gynecological endocrinology 5th ed 1989 Williams &Wilkins Baltimore
3. MR. Henzl Gonadotropin-releasing hormone analogs: update on new findings Am J Obstet Gynecol 166 1992 757 761
4. M Hornstein AA Yuzpe KA Burry WL Heinrichs VL Buttram Jr ES. Orwoll Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain Fertil Steril 63 1995 955 962
5. SAS Institute Inc SAS user's guide: statistics, version 6 1990 The Institute Cary (NC)
6. JL. Fleiss Statistical methods for rates and proportions 1981 John Wiley &Sons New York
7. P Armitage G. Berry Statistical methods in medical research 2nd ed 1987 Blackwell Scientific Oxford (United Kingdom) 107 112
8. ES Orwoll AA Yuzpe KA Burry WL Heinrichs VL Buttram Jr MD. Hornstein Nafarelin therapy in endometriosis: long-term effects on bone mineral content Am J Obstet Gynecol 171 1994 1221 1225
9. K Newhall-Perry L Holloway L Osburn SE Monroe WL Heinrichs MR Henzl Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis Am J Obstet Gynecol 173 1995 824 829
10. RL Barbieri AMC. Gordon Hormonal therapy for endometriosis: the estradiol target Fertil Steril 56 1991 820 822
11. RL. Barbieri Hormone treatment of endometriosis: the estrogen threshold hypothesis Am J Obstet Gynecol 166 1992 740 745
12. SK Agarwal C Hamrang HL Judd the Nafarelin Study Group. Efficacy and safety of intranasal nafarelin compared with intramuscular leuprolide depot for the treatment of endometriosis: changes in bone mineral density and vasomotor symptoms J Reprod Med 42 1997 413 423
13. MR Henzl SL Corson K Moghissi VC Buttram C Berquist J. Jacobson Administration of nasal nafarelin as compared with oral danazol for endometriosis N Engl J Med 318 1988 485 489
14. U Cirkel KW Schweppe H Ochs HP. Schneider Effects of LH-RH agonist therapy in the treatment of endometriosis DR Chadha WNP Willemsen Volume 225: gonadotropin down-regulation in gynecological practice. 1986 Alan R. Liss New York 189
15. AM Dlugi JD Miller J Knittle Lupron Study Group Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo controlled, double-blind study Fertil Steril 54 1990 419 427
16. RW. Shaw Goserelin depot preparation of LH-RH analogue used in the treatment of endometriosis DR Chadha VC Buttram Jr Volume 323: current concepts in endometriosis. 1990 Alan R. Liss New York 383